Clinical Trial: A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07733180) titled 'A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC' on July 22.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line treatment in Japanese participants with previously untreated, unresectable locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC).

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Advanced Esophageal Squamous Cell Carcinom...